Why Ovarian Cancer Is Called the Silent Killer + New Hope with Lifyorli New Drug | Expert Interview episode artwork

EPISODE · Jul 6, 2026 · 43 MIN

Why Ovarian Cancer Is Called the Silent Killer + New Hope with Lifyorli New Drug | Expert Interview

from DoctorPodcasts || Cykiert Files · host Robert Cykiert, M.D. - Physician creator, writer, producer, director and host.

New hope for ovarian cancer patients! In this in-depth interview, leading gynecologic oncologist Dr. Alexander Olawaiye discusses the devastating "silent killer" — ovarian cancer — and the recent FDA approval of Lifyorli (relacorilant), a groundbreaking new drug for platinum-resistant cases. In this #DoctorPodcasts episode # 154, Dr. Olawaiye, a key investigator in the pivotal ROSella Phase 3 trial, explains the biology of the disease, why early detection is so difficult, standard treatments, and how Lifurley + nab-paclitaxel significantly improves progression-free and overall survival. Key Topics Covered: Why ovarian cancer is often diagnosed late (Stage 3–4)Symptoms, diagnosis challenges, and current limitations in screening.Platinum-resistant ovarian cancer explained.How Lifyorli works (cortisol receptor mechanism).ROSella trial results: survival benefits and safety profile.Future of antibody-drug conjugates and AI in gynecologic oncology.Importance of clinical trial participation.Watch this DoctorPodcasts Episode 154 with host, Dr. Robert Cykiert.Guest:Dr. Alexander Olawaiye, MDProfessor of Gynecologic Oncology, University of Pittsburgh / Magee-Women’s HospitalKey Investigator, ROSella Trial Timestamps:0:00 Intro & Welcome2:14 What is ovarian cancer? Why the "silent killer"?3:56 Symptoms and late-stage diagnosis6:16 How ovarian cancer is diagnosed (CA-125, imaging, etc.)8:04 Why current screening (CA-125, ultrasound, MRI) doesn't work13:28 Prognosis and platinum-based chemotherapy15:29 Platinum-resistant ovarian cancer explained18:35 Lifurley (relacorilant) + nab-paclitaxel: New FDA-approved treatment21:04 Mechanism of action and how it overcomes resistance23:55 ROSella Phase 3 Trial results – survival data30:52 Side effects and tolerability32:33 Future developments (antibody-drug conjugates, more trials)37:09 Importance of research & clinical trials41:45 Final thoughts and hope for patientsIf you or a loved one has been affected by ovarian cancer, this episode offers critical, up-to-date information from a top expert. Subscribe for more physician-led discussions on breakthrough treatments, cancer care, and women's health. Like, comment, and share to help others find this information! #OvarianCancer #Lifurley #CancerTreatment #ROSellaTrial #GynecologicOncology #WomensHealth #NewCancerDrug #PlatinumResistant #HarvardTrained #ClinicalTrials

Episode metadata supplied by the publisher feed · Published Jul 6, 2026

Embed this episode

Ready to play

Why Ovarian Cancer Is Called the Silent Killer + New Hope with Lifyorli New Drug | Expert Interview

0:00 43:30

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of DoctorPodcasts || Cykiert Files?

This episode is 43 minutes long.

When was this DoctorPodcasts || Cykiert Files episode published?

This episode was published on July 6, 2026.

Can I download this DoctorPodcasts || Cykiert Files episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!